Breaking News Instant updates and real-time market news.

AVXS

AveXis

$44.55

2.36 (5.59%)

07:42
10/06/16
10/06
07:42
10/06/16
07:42

AveXis attractive acquisition target, price target to $71 at Goldman

Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.

  • 06

    Nov

AVXS AveXis
$44.55

2.36 (5.59%)

08/17/16
WELS
08/17/16
UPGRADE
WELS
Outperform
AveXis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded AveXis (AVXS) to Outperform after speaking to five experts in spinal muscular atrophy. The experts were impressed with both Ionis Pharmaceuticals (IONS)/Biogen's (BIIB) nusinersen and AveXis' gene therapy AVXS101, and suggested that likely incomplete restoration of normal neuromuscular phenotype could prompt combination use of both treatments, Birchenough tells investors in a research note. The analyst raised his price target range for AveXis shares to $56-$61 from $30-$32. The stock closed yesterday down $1.91 to $41.66.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies thinks it found baby in AveXis trial that is walking
Jefferies analyst Biren Amin believes a video posted online of a baby walking has a "strong likelihood" of being a patient in AveXis' AVXS-101 trial. AVXS-101 is a gene therapy candidate in Phase I testing for spinal muscular atrophy. The near 20 month old's achievement to walk "is significant" given that she is a Type 1 SMA baby with 2 copy number and would not in any normal circumstance be expected to walk, Amin tells investors in a research note. The analyst points out that his finding online comes ahead of AveXis' plan to disclose patient data on motor milestones from its Phase 1 trial later this year. To reflect increased confidence in AVXS-101's prospects, Amin raised his price target for the shares to $50 from $42. The clinical-stage gene therapy company, formerly known as Biolife Cell Bank, closed Friday up 83c to $41.72.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.

TODAY'S FREE FLY STORIES

MTN

Vail Resorts

$160.92

-1.81 (-1.11%)

20:25
12/08/16
12/08
20:25
12/08/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MON

Monsanto

$104.70

-0.71 (-0.67%)

20:17
12/08/16
12/08
20:17
12/08/16
20:17
Hot Stocks
Washington sues Monsanto over PCB contamination »

Washington Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 27

    Jan

USAC

USA Compression

$18.01

-0.14 (-0.77%)

20:15
12/08/16
12/08
20:15
12/08/16
20:15
Syndicate
USA Compression 4.5M share Spot Secondary priced at $16.25 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ICHR

Ichor Holdings

20:11
12/08/16
12/08
20:11
12/08/16
20:11
Syndicate
Ichor Holdings 5.9M share IPO priced at $9.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:53
12/08/16
12/08
19:53
12/08/16
19:53
Periodicals
YouTube-NMPA settlement estimated at over $40M, NY Times says »

The agreement between…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:46
12/08/16
12/08
19:46
12/08/16
19:46
Hot Stocks
YouTube reaches agreement to pay out unclaimed song royalties »

The National Music…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

ATH

Athene Holding

19:33
12/08/16
12/08
19:33
12/08/16
19:33
Syndicate
Athene Holding 27M share IPO priced at $40.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MMM

3M

$175.88

-0.17 (-0.10%)

19:29
12/08/16
12/08
19:29
12/08/16
19:29
Hot Stocks
3M to sell identity management business to Gemalto for $850M »

3M announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SMI

SMIC

$5.99

-0.54 (-8.27%)

19:24
12/08/16
12/08
19:24
12/08/16
19:24
Hot Stocks
SMIC announces 10-for-1 reverse stock split »

Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$62.61

0.41 (0.66%)

19:10
12/08/16
12/08
19:10
12/08/16
19:10
Hot Stocks
Ventas raises quarterly dividend 6% to 77.5c per share »

Ventas said that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:08
12/08/16
12/08
19:08
12/08/16
19:08
Periodicals
Wells Fargo chairman appointed to sales investigation committee, Reuters says »

Wells Fargo chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:03
12/08/16
12/08
19:03
12/08/16
19:03
Periodicals
Former Wells Fargo managers file suit over fake accounts, Bloomberg reports »

Three former Wells Fargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

EIX

Edison International

$69.44

-0.17 (-0.24%)

18:42
12/08/16
12/08
18:42
12/08/16
18:42
Hot Stocks
Edison International raises annual dividend 13% to $2.17 per share »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLM

PolyMet Mining

$0.87

0.0001 (0.01%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Earnings
Breaking Earnings news story on PolyMet Mining »

PolyMet Mining reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$18.38

0.18 (0.99%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Hot Stocks
Match Group launches 'Swipe Ventures,' says Tinder CEO to step down »

Match Group's Tinder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

18:18
12/08/16
12/08
18:18
12/08/16
18:18
Hot Stocks
Biogen to present aducanumab Phase 1b data at CTAD meeting »

Biogen announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

HIVE

Aerohive

$5.41

0.18 (3.44%)

18:17
12/08/16
12/08
18:17
12/08/16
18:17
Hot Stocks
Discovery Group reports 9.1% stake in Aerohive Networks, sends letter to board »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

, ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

18:05
12/08/16
12/08
18:05
12/08/16
18:05
Periodicals
Outrigger Energy nears sale to midstream services provider, Forbes says »

Private-equity backed…

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

TRGP

Targa Resources

$54.20

0.38 (0.71%)

ETP

Energy Transfer Partners

$35.13

0.55 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$78.65

0.96 (1.24%)

18:02
12/08/16
12/08
18:02
12/08/16
18:02
Hot Stocks
Post Holdings settles egg antitrust class action claims »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENZN

Enzon

$0.44

-0.0027 (-0.62%)

17:54
12/08/16
12/08
17:54
12/08/16
17:54
Hot Stocks
Icahn says enters standstill pact with Enzon »

In an amended filing on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$52.27

0.15 (0.29%)

17:53
12/08/16
12/08
17:53
12/08/16
17:53
Hot Stocks
Leidos awarded $350M government contract »

Leidos, Reston, Virginia,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:50
12/08/16
12/08
17:50
12/08/16
17:50
Hot Stocks
Dominion Diamond sees FY17 production at Ekati diamond mine 4.5M carats »

Sees FY17 Ekati diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FNSR

Finisar

$34.13

1.89 (5.86%)

, AVGO

Broadcom

$170.71

2.16 (1.28%)

17:49
12/08/16
12/08
17:49
12/08/16
17:49
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

FNSR

Finisar

$34.13

1.89 (5.86%)

AVGO

Broadcom

$170.71

2.16 (1.28%)

GLPG

Galapagos NV

$58.95

0.71 (1.22%)

XTLY

Xactly

$14.35

0.35 (2.50%)

RH

Restoration Hardware

$38.99

1.05 (2.77%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

NCS

NCI Building

$17.85

0.6 (3.48%)

FRED

Fred's

$10.84

0.15 (1.40%)

USAC

USA Compression

$18.01

-0.14 (-0.77%)

FRO

Frontline

$7.71

0.37 (5.04%)

WSM

Williams-Sonoma

$56.90

0.61 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 14

    Dec

  • 09

    Dec

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

, ANTM

Anthem

$146.61

1.41 (0.97%)

17:48
12/08/16
12/08
17:48
12/08/16
17:48
Hot Stocks
Citron's Andrew Left: 'By no means' calling Express Scripts a fraud or zero »

Speaking in a CNBC…

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

ANTM

Anthem

$146.61

1.41 (0.97%)

CVS

CVS Health

$78.11

-2.42 (-3.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:45
12/08/16
12/08
17:45
12/08/16
17:45
Earnings
Dominion Diamond reports Q3 EPS 34c with items, consensus (32c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.